Table 2.
Overrepresented GO categories identified by DAVID analysis for the group of significantly regulated transcripts between FSL and SD rats. Counts represent the number of genes from the up- (A) or down- (B) regulated gene lists submitted that were identified as components of the noted GO term. Statistical testing for significant enrichment was carried out using EASE, a modified, more conservative version of the Fisher Exact Test.
| Term | Count | p-Value | Gene symbols |
|---|---|---|---|
| A. FSL up-regulated | |||
| Protein complex assembly | 7 | 0.014 | CNTF, P2RX4, pfdn6, TRADD, MIS12, polr2i, ATL1 |
| Protein complex biogenesis | 7 | 0.014 | CNTF, P2RX4, pfdn6, TRADD, MIS12, polr2i, ATL1 |
| Response to drug | 6 | 0.020 | mgst1, sst, COMT, SLC1A3, Abcg2, ACSL1 |
| Negative regulation of cell proliferation | 5 | 0.038 | COMT, THY1, GTPBP4, Fntb, CDH13 |
| Regulation of axonogenesis | 3 | 0.042 | CNTF, THY1, MBP |
| Regulation of cell migration | 4 | 0.045 | sst, THY1, GTPBP4, CDH13 |
| Macromolecular complex assembly | 7 | 0.045 | CNTF, P2RX4, pfdn6, TRADD, MIS12, polr2i, ATL1 |
| Cellular amino acid derivative metabolic process | 4 | 0.047 | mgst1, ddc, COMT, SLC1A3 |
| B. FSL down-regulated | |||
| Oxidation reduction | 16 | 0.001 | DPYD, cat, Cyp4f1, retsat, NQO2, RTN4IP1, PXDN, ME3, RGD1304982, PYROXD2, etfB, FMO5, AOX1, Cyp4f4, DEGS1, Aldh3b1 |
| Regulation of myeloid leukocyte mediated immunity | 3 | 0.009 | C3, PLD2, Fcgr2b |
| Immunoglobulin mediated immune response | 4 | 0.011 | C3, MLH1, Fcgr2b, C1qa |
| B cell mediated immunity | 4 | 0.013 | C3, MLH1, Fcgr2b, C1qa |
| Positive regulation of immune effector process | 4 | 0.013 | C3, PLD2, Fcgr2b, NP |
| Antigen processing and presentation of peptide antigen via MHC class I | 3 | 0.021 | Fcgr2b, RT1-S3, RT1-EC2 |
| Phosphoinositide-mediated signaling | 4 | 0.022 | F2R, PIK3C3, Pthr1, HCRT |
| Lymphocyte mediated immunity | 4 | 0.022 | C3, MLH1, Fcgr2b, C1qa |
| Regulation of endocytosis | 4 | 0.024 | C3, PLD2, Fcgr2b, STON2 |
| Positive regulation of transport | 7 | 0.026 | F2R, C3, PLD2, Fcgr2b, HCRT, AKAP5, ACSL5 |
| Adaptive immune response | 4 | 0.027 | C3, MLH1, Fcgr2b, C1qa |
| Adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains | 4 | 0.027 | C3, MLH1, Fcgr2b, C1qa |
| Activation of protein kinase C activity by G-protein coupled receptor protein signaling pathway | 3 | 0.028 | F2R, HCRT, LOC497978 |
| dGTP metabolic process | 2 | 0.029 | Dguok, NP |
| Regulation of leukocyte mediated immunity | 4 | 0.036 | C3, PLD2, Fcgr2b, NP |
| Leukocyte mediated immunity | 4 | 0.037 | C3, MLH1, Fcgr2b, C1qa |
| Deoxyribonucleoside catabolic process | 2 | 0.038 | DPYD, NP |
| Positive regulation of calcium ion transport | 3 | 0.041 | F2R. HCRT, AKAP5 |
| Positive regulation of type IIa hypersensitivity | 2 | 0.048 | C3, Fcgr2b |
| Regulation of type IIa hypersensitivity | 2 | 0.048 | C3, Fcgr2b |
| Positive regulation of myeloid leukocyte mediated immunity | 2 | 0.048 | C3, Fcgr2b |
| Regulation of type II hypersensitivity | 2 | 0.048 | C3, Fcgr2b |
| Positive regulation of type II hypersensitivity | 2 | 0.048 | C3, Fcgr2b |
| Positive regulation of endocytosis | 3 | 0.048 | C3, PLD2, Fcgr2b |
Abbreviations: Ciliary neurotropic factor, CNTF; purinergic receptor P2X, ligand-gated ion channel 4, P2RX4; prefoldin 6, pfdn6; TNFRSF1A–associated via death domain, TRADD; MIS12, MIND kinetochore complex component, homolog (yeast), MIS12; polymerase (RNA) II (DNA directed) polypeptide I, 14.5 kDa, polr2i; spastic paraplegia 3A homolog (human), ATL1; microsomal glutathione S-transferase 1, mgst1; somatostatin, sst; catechol-O-methyltransferase, COMT; solute carrier family 1 (glial high affinity glutamate transporter), member 3, SLC1A3; ATP-binding cassette, sub-family G (WHITE), member 2, Abcg2; acyl-CoA synthetase long-chain family member 1, ACSL1; Thy-1 cell surface antigen, THY1; similar to Nucleolar GTP-binding protein 1 (chronic renal failure gene protein) (GTP-binding protein NGB); similar to G protein-binding protein CRFG; GTP binding protein 4; similar to isopentenyl diphosphate delta-isomerase type 2, GTPBP4; farnesyltransferase, CAAX box, beta, Fntb; cadherin 13, CDH13; myelin basic protein, MBP; dopa decarboxylase (aromatic L-amino acid decarboxylase), ddc; dihydropyrimidine dehydrogenase, DPYD; catalase, cat; cytochrome P450, family 4, subfamily f, polypeptide 1, Cyp4f1; retinol saturase (all trans retinol 13,14 reductase), retsat; NAD(P)H dehydrogenase, quinone 2, NQO2; reticulon 4 interacting protein 1, RTN4IP1; peroxidasin homolog (Drosophila), PXDN; malic enzyme 3, NADP(+)-dependent, mitochondrial, ME3; similar to RIKEN cDNA 2810025M15, RGD1304982; pyridine nucleotide-disulphide oxidoreductase domain 2, PYROXD2; electron-transfer-flavoprotein, beta polypeptide, etfB; flavin containing monooxygenase 5, FMO5; aldehyde oxidase 1, AOX1; cytochrome P450, family 4, subfamily f, polypeptide 4, Cyp4f4; degenerative spermatocyte homolog 1, lipid desaturase (Drosophila), DEGS1; aldehyde dehydrogenase 3 family, member B1, Aldh3b1; complement component 3, C3; phospholipase D2, PLD2; Fc fragment of IgG, low affinity IIb, receptor (CD32); Fc fragment of IgG, low affinity IIa, receptor (CD32), Fcgr2b; mutL homolog 1 (E. coli), MLH1; complement component 1, q subcomponent, alpha polypeptide, C1qa; nucleoside phosphorylase, NP; histocompatibility 2, T region locus 23; histocompatibility 2, T region locus 24, RT1-S3; RT1 class Ib, locus Aw2, RT1-EC2; coagulation factor II (thrombin) receptor, F2R; phosphoinositide-3-kinase, class 3, PIK3C3; parathyroid hormone receptor 1, Pthr1; hypocretin, HCRT; stonin 2, STON2; A kinase (PRKA) anchor protein 5, AKAP5; acyl-CoA synthetase long-chain family member 5, ACSL5; similar to diacylglycerol kinase epsilon, LOC497978; deoxyguanosine kinase, Dguok.